VIVOS INC. Files 8-K/A Amendment
Ticker: RDGL · Form: 8-K/A · Filed: Sep 24, 2025 · CIK: 1449349
| Field | Detail |
|---|---|
| Company | Vivos Inc (RDGL) |
| Form Type | 8-K/A |
| Filed Date | Sep 24, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $192,000, $3,000, $12,000, $30.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, corporate-governance, material-agreement
TL;DR
VIVOS INC. amended its 8-K filing, updating info on material agreements and exec changes.
AI Summary
VIVOS INC. filed an amendment (8-K/A) on September 24, 2025, to a previous report dated September 15, 2025. The amendment pertains to a material definitive agreement, the departure of directors or officers, and compensatory arrangements. The company, formerly known as ADVANCED MEDICAL ISOTOPE Corp, is incorporated in Delaware and headquartered in Kennewick, WA.
Why It Matters
This amendment provides updated information regarding significant corporate events, including material agreements and changes in executive or director positions, which could impact investor understanding of the company's governance and strategic direction.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings can indicate new or revised material information, requiring investors to re-evaluate the company's status and potential risks.
Key Players & Entities
- VIVOS INC. (company) — Registrant
- ADVANCED MEDICAL ISOTOPE Corp (company) — Former Company Name
- September 15, 2025 (date) — Date of earliest event reported
- September 24, 2025 (date) — Filing Date of Amendment
- Delaware (jurisdiction) — State of Incorporation
- Kennewick, WA (location) — Principal Business Address
FAQ
What specific material definitive agreement is being amended or clarified in this 8-K/A filing?
The filing indicates an amendment related to 'Entry into a Material Definitive Agreement' but does not specify the agreement's details within the provided text.
What changes are being reported regarding directors or officers?
The filing notes 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item information, suggesting changes in company leadership.
What is the significance of the filing being an 8-K/A (Amendment No. 1)?
An 8-K/A indicates that VIVOS INC. is amending or supplementing a previously filed 8-K report, suggesting new or corrected information is being provided.
When was the original event that this amendment pertains to?
The earliest event reported in the amendment is dated September 15, 2025.
What was VIVOS INC. previously known as?
VIVOS INC. was formerly known as ADVANCED MEDICAL ISOTOPE Corp.
Filing Stats: 1,377 words · 6 min read · ~5 pages · Grade level 11.9 · Accepted 2025-09-23 19:19:44
Key Financial Figures
- $192,000 — l receive: (i) an annual base salary of $192,000; (ii) a monthly grant of $3,000 in shar
- $3,000 — ry of $192,000; (ii) a monthly grant of $3,000 in shares common stock of the Company a
- $12,000 — ) compensation for consulting a rate of $12,000 per month; and (ii) a monthly grant of
- $30.0 million — capital financing rounds totaling over $30.0 million. Mr. Swanberg has been actively engaged
Filing Documents
- form8-ka.htm (8-K/A) — 51KB
- 0001493152-25-014694.txt ( ) — 211KB
- rdgl-20250915.xsd (EX-101.SCH) — 3KB
- rdgl-20250915_lab.xml (EX-101.LAB) — 33KB
- rdgl-20250915_pre.xml (EX-101.PRE) — 22KB
- form8-ka_htm.xml (XML) — 4KB
02
Item 5.02. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Brad Allan Weeks On September 15, 2025, Vivos Inc. (the " Company ") appointed Brad Allan Weeks as President of the Company, pursuant to an employment agreement entered into between the Company and Mr. Weeks (the " Employment Agreement "). From 2024 to September 15, 2025, Mr. Weeks served as the Company's Business Development Manager for both the IsoPet and RadioGel divisions . Prior to his engagement with the Company, Mr. Weeks served as Quality Assurance and Regulatory Affairs Engineer for Cadwell Industries, Inc. The Employment Agreement provides that Mr. Weeks shall serve as President for a term effective September 1, 2025, ending on December 31, 2027, which term may be extended by written agreement of both parties. Pursuant to the Employment Agreement, Mr. Weeks shall receive: (i) an annual base salary of $192,000; (ii) a monthly grant of $3,000 in shares common stock of the Company at the end of each fiscal quarter based on the closing price of the Company's common stock at the end of such fiscal quarter; and (iii) customary benefits and reimbursement for reasonable out-of-pocket business expenses. The Employment Agreement also provides customary provisions relating to, among other things, clawback rights, confidentiality, non-competition, and non-solicitation. Mr. Weeks is a seasoned leader with extensive experience in the medical device and biotechnology sectors. As President Brad plays a pivotal role in business development, team expansion, and strategic partnerships, contributing to the Company's growth in targeted cancer therapies that deliver radioactive agents directly to tumors while minimizing damage to healthy tissue. Brad has built a distinguished career in healthcare innovation, holding leadership positions at organizations focused on advancing medical techn
SIGNATURES
SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. VIVOS INC. Date: September 23, 2025 By: /s/ Michael K. Korenko Name: Michael K. Korenko Title: Chief Executive Officer